- The company is enjoying multiple growth vectors pushing the shares higher as its home infusion solutions are a major cost saver for the healthcare system.
- It also sprouts an attractive razor and blade business model.
- However, we see little reason for further valuation multiple expansion as the shares seem fairly fully valued.